Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: A potential new therapeutic approach

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Santos Martínez, Nancy ^a,b   Díaz, Lorenza ^a   Ordaz Rosado, David ^a   García Quiroz, Janice ^a,b   Barrera, David ^a   Avila, Euclides ^a   Halhali, Ali ^a   Medina Franco, Heriberto ^a   Ibarra Sánchez, María J ^a   Esparza López, José ^a   Camacho, Javier ^b   Larrea, Fernando ^a   García Becerra, Rocío ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Breast cancer; Calcitriol; Estrogen receptor; Hormonal therapy; VDR

Indexed keywords

CALCITRIOL; CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PROLACTIN; VITAMIN D RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN D1 GENE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EAG1 GENE; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PROLACTIN GENE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GENE; UPREGULATION; WESTERN BLOTTING;

BREAST NEOPLASMS; CALCITRIOL; CELL LINE, TUMOR; CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTORS, CALCITRIOL;

EID: 84897436484     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-230     Document Type: Article

References (48)

1. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005, 205(2):248-254. 10.1002/path.1691, 15641021.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988, 15(2 Suppl 1):20-25.
4. McGuire WL, Osborne CK, Clark GM, Knight WA. Steroid hormone receptors and carcinoma of the breast. Am J Physiol 1982, 243(2):E99-E102.
5. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005, 123(1):21-27. 10.1309/4WV79N2GHJ3X1841, 15762276.
6. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99(4):283-290. 10.1093/jnci/djk050, 17312305.
7. Clarke MJ. WITHDRAWN: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2008, 4. CD000486.
8. Johnston SR. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs 1997, 8(10):911-930. 10.1097/00001813-199711000-00002, 9436634.
9. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008, 283(45):31079-31086. 10.1074/jbc.M806041200, 2576549, 18790736.
10. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007, 13(23):7029-7036. 10.1158/1078-0432.CCR-07-0587, 18056179.
11. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001, 15(8):1344-1359.
12. Fife RS, Sledge GW, Proctor C. Effects of vitamin D3 on proliferation of cancer cells in vitro. Cancer Lett 1997, 120(1):65-69. 10.1016/S0304-3835(97)00298-X, 9570387.
13. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996, 58(4):367-376. 10.1016/0960-0760(96)00055-6, 8903420.
14. Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C, Berciano MT, Lafarga M, Munoz A. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75(3):193-207. 10.1111/j.1432-0436.2006.00131.x, 17288543.
15. Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA, Hulka BS. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 1999, 2(3):283-291.
16. Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab 1997, 82(1):118-122.
17. Yao S, Ambrosone CB. Associations between vitamin D deficiency and risk of aggressive breast cancer in African-American women. J Steroid Biochem Mol Biol 2012, 136:337-341.
18. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 1991, 51(1):239-244.
19. Garcia-Becerra R, Diaz L, Camacho J, Barrera D, Ordaz-Rosado D, Morales A, Ortiz CS, Avila E, Bargallo E, Arrecillas M, Halhali A, Larrea F. Calcitriol inhibits Ether-a go-go potassium channel expression and cell proliferation in human breast cancer cells. Exp Cell Res 2010,
20. Swami S, Krishnan AV, Feldman D. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 2000, 6(8):3371-3379.
21. Garcia-Quiroz J, Garcia-Becerra R, Barrera D, Santos N, Avila E, Ordaz-Rosado D, Rivas-Suarez M, Halhali A, Rodriguez P, Gamboa-Dominguez A, Medina-Franco H, Camacho J, Larrea F, Diaz L. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy. PLoS One 2012, 7(9):e45063. 10.1371/journal.pone.0045063, 3440370, 22984610.
22. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 1997, 42(1):31-41. 10.1023/A:1005772432465, 9116316.
23. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB. Regulation of estrogen receptor-alpha gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 1999, 75(4):640-651. 10.1002/(SICI)1097-4644(19991215)75:4<640::AID-JCB10>3.0.CO;2-8, 10572247.
24. Davoodi F, Brenner RV, Evans SR, Schumaker LM, Shabahang M, Nauta RJ, Buras RR. Modulation of vitamin D receptor and estrogen receptor by 1,25(OH)2-vitamin D3 in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 1995, 54(3-4):147-153.
25. Li Z, Bustos V, Miner J, Paulo E, Meng ZH, Zlotnikov G, Ljung BM, Dairkee SH. Propagation of genetically altered tumor cells derived from fine-needle aspirates of primary breast carcinoma. Cancer Res 1998, 58(23):5271-5274.
26. Tesch M, Shawwa A, Henderson R. Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Pathol 1993, 99(1):8-12.
27. Maurer U, Jehan F, Englert C, Hubinger G, Weidmann E, DeLuca HF, Bergmann L. The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor. Biol Chem 2001, 276(6):3727-3732.
28. Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, Picard D, Maggiolini M. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. PloS one 2011, 6(1):e16631. 10.1371/journal.pone.0016631, 3031608, 21304949.
29. Almeras L, Eyles D, Benech P, Laffite D, Villard C, Patatian A, Boucraut J, Mackay-Sim A, McGrath J, Feron F. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics 2007, 7(5):769-780. 10.1002/pmic.200600392, 17295352.
30. Hussain-Hakimjee EA, Mehta RG. Regulation of steroid receptor expression by 1alpha-hydroxyvitamin D5 in hormone-responsive breast cancer cells. Anticancer Res 2009, 29(9):3555-3561.
31. Duan R, Ginsburg E, Vonderhaar BK. Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells. Mol Cell Endocrinol 2008, 281(1-2):9-18.
32. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993, 13(6):3577-3587. 359827, 8497271.
33. Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1994, 31(1):95-105. 10.1007/BF00689680, 7981461.
34. Pardo LA, Suhmer W. Eag1 as a cancer target. Expert Opin Ther Targets 2008, 12(7):837-843. 10.1517/14728222.12.7.837, 18554152.
35. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988, 37(5):889-895. 10.1016/0006-2952(88)90177-3, 2830885.
36. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46(12 Suppl):2884-2888.
37. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21(13):2933-2942. 10.1093/bioinformatics/bti473, 15860560.
38. Kos M, Reid G, Denger S, Gannon F. Minireview: genomic organization of the human ERalpha gene promoter region. Mol Endocrinol 2001, 15(12):2057-2063.
39. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Canc 2003, 10(2):179-186.
40. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocrine reviews 1995, 16(5):559-589. 10.1210/edrv-16-5-559, 8529572.
41. Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84(8):580-591. 10.1093/jnci/84.8.580, 1556769.
42. Vignon F, Bouton MM, Rochefort H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 1987, 146(3):1502-1508. 10.1016/0006-291X(87)90819-9, 3304294.
43. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998, 52(1-3):1-15.
44. Ouadid-Ahidouch H, Ahidouch A. K + channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J Membr Biol 2008, 221(1):1-6. 10.1007/s00232-007-9080-6, 18060344.
45. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 2003, 106(1):8-16. 10.1002/ijc.11172, 12794751.
46. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A. Vitamin D (3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001, 154(2):369-387. 10.1083/jcb.200102028, 2150773, 11470825.
47. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001, 91(12):2431-2439. 10.1002/1097-0142(20010615)91:12<2431::AID-CNCR1278>3.0.CO;2-3, 11413535.
48. Masuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther 2006, 5(4):797-808. 10.1158/1535-7163.MCT-05-0539, 16648549.